Skip to Content

Pred-Moxi-Nepaf (moxifloxacin / nepafenac / prednisolone ophthalmic) Disease Interactions

There are 3 disease interactions with Pred-Moxi-Nepaf (moxifloxacin / nepafenac / prednisolone ophthalmic):

Major

NSAIDs (applies to Pred-Moxi-Nepaf) asthma

Major Potential Hazard, High plausibility.

Approximately 10% of patients with asthma may have aspirin-sensitive asthma, characterized by nasal polyposis, pansinusitis, eosinophilia, and precipitation of asthma and rhinitis attacks after ingestion of aspirin. The use of aspirin in these patients has been associated with severe bronchospasm and fatal anaphylactoid reactions. Since cross-sensitivity has been noted between aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), therapy with any NSAID should be avoided in asthmatic patients with a history of aspirin or other NSAID sensitivity, and administered cautiously in all patients with preexisting asthma. Prior to initiating therapy with NSAIDs, patients should be questioned about previous allergic-type reactions to these agents. Salicylate salts, salsalate, salicylamide, and acetaminophen may be appropriate alternatives in patients with a history of NSAID-induced bronchospasm, since cross-sensitivity to these agents appears to be low. However, cross-sensitivity has been demonstrated occasionally with high dosages of these agents (e.g., acetaminophen >= 1000 mg), thus it may be appropriate to initiate therapy with low dosages and increase gradually. There is some evidence suggesting that COX-2 inhibitors may be safely used in patients with aspirin-sensitive asthma, although the labeling for these products contraindicate such use. If necessary, aspirin desensitization may also be attempted in some patients under medical surveillance.

References

  1. "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals, East Hanover, NJ.
  3. Stevenson DD, Simon RA "Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma." J Allerg Clin Immunol 108 (2001): 47-51
  4. "Product Information. Feldene (piroxicam)." Pfizer US Pharmaceuticals, New York, NY.
  5. "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc, Palo Alto, CA.
  6. Stevenson DD, Hougham AJ, Schrank PJ, Goldlust MB, Wilson RR "Salsalate cross-sensitivity in aspirin-sensitive patients with asthma." J Allergy Clin Immunol 86 (1990): 749-58
  7. Settipane RA, Stevenson DD "Cross sensitivity with acetaminophen in aspirin-sensitive subjects with asthma." J Allergy Clin Immunol 84 (1989): 26-33
  8. "Product Information. Mobic (meloxicam)" Boehringer-Ingelheim, Ridgefield, CT.
  9. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):
  10. "Product Information. Clinoril (sulindac)." Merck & Co, Inc, West Point, PA.
  11. Lewis RV "Severe asthma after naproxen." Lancet 05/30/87 (1987): 1270
  12. Ayres JG, Fleming DM, Whittington RM "Asthma death due to ibuprofen." Lancet 05/09/87 (1987): 1082
  13. Carmona MJ, Blanca M, Garcia A, Fernandez S, Burgos F, Miranda A, Vega JM, Garcia J "Intolerance to piroxicam in patients with adverse reactions to nonsteroidal antiinflammatory drugs." J Allergy Clin Immunol 90 (1992): 873-9
  14. Shapiro N "Acute angioedema after ketorolac ingestion - report of case." J Oral Maxillofac Surg 52 (1994): 626-7
  15. Haddow GR, Riley E, Isaacs R, McSharry R "Ketorolac, nasal polyposis, and bronchial asthma: a cause for concern." Anesth Analg 76 (1993): 420-2
  16. Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J, Cohn J, Rubin P, Drazen JM "The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin." Am Rev Respir Dis 148 (1993): 1447-51
  17. Cohen RD, Bateman ED, Potgieter PD "Near-fatal bronchospasm in an asthmatic patient following ingestion of flurbiprofen. A case report." S Afr Med J 61 (1982): 803
  18. "Product Information. Bextra (valdecoxib)." Pharmacia Corporation, Peapack, NJ.
  19. "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical, Raritan, NJ.
  20. "Product Information. Relafen (nabumetone)." SmithKline Beecham, Philadelphia, PA.
  21. Schreuder G "Ketoprofen: possible idiosyncratic acute bronchospasm." Med J Aust 152 (1990): 332-3
  22. Zikowski D, Hord AH, Haddox JD, Glascock J "Ketorolac-induced bronchospasm." Anesth Analg 76 (1993): 417-9
  23. "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  24. "Product Information. Nalfon (fenoprofen)." Xspire Pharma, Ridgeland, MS.
  25. Woessner KM, Simon RA, Stevenson DD "The safety of celecoxib in patients with aspirin-sensitive asthma." Arthritis Rheum 46 (2002): 2201-6
  26. "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  27. Dahlen B, Szczeklik A, Murray HH "Celecoxib in patients with asthma and aspirin intolerance." N Engl J Med 344 (2000): 142
  28. "Product Information. Indocin (indomethacin)." Merck & Co, Inc, West Point, PA.
  29. "Product Information. Daypro (oxaprozin)." Searle, Skokie, IL.
  30. "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
  31. Lee TH "Mechanism of aspirin sensitivity." Am Rev Respir Dis 145 (1992): s34-6
  32. "Product Information. Celebrex (celecoxib)." Searle, Chicago, IL.
  33. Salberg DJ, Simon MR "Severe asthma induced by naproxen: a case report and review of the literature." Ann Allergy 45 (1980): 372-5
  34. "Product Information. Vioxx (rofecoxib)." Merck & Co, Inc, West Point, PA.
  35. Szczeklik A, Stevenson DD "Aspirin-induced asthma: Advances in pathogenesis and management." J Allerg Clin Immunol 104 (1999): 5-13
  36. Chan TY "Severe asthma attacks precipitated by NSAIDs." Ann Pharmacother 29 (1995): 199
  37. Nasser SMS, Lee TH "Aspirin-induced early and late asthmatic responses." Clin Exp Allergy 25 (1995): 1-3
  38. Lee TH "Mechanism of bronchospasm in aspirin-sensitive asthma." Am Rev Respir Dis 148 (1993): 1442-3
View all 38 references
Major

Ophthalmic corticosteroids (applies to Pred-Moxi-Nepaf) ocular infections

Major Potential Hazard, High plausibility.

The use of ophthalmic corticosteroids is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella; fungal diseases of ocular structures; mycobacterial infections, including tuberculosis, of the eye; and any acute, purulent, untreated ocular infections. Corticosteroids may decrease host resistance to infectious agents, thus prolonging the course and/or exacerbating the severity of the infection while encouraging the development of new or secondary infection. In addition, administration of ophthalmic corticosteroids in severe ocular disease, especially acute herpes simplex keratitis, may lead to excessive corneal and scleral thinning, increasing the risk for perforation. In less serious ocular infections, therapy with ophthalmic corticosteroids may be administered but only with caution and accompanied by appropriate antimicrobial agents. Besides compromising host immune response, corticosteroids may also mask the symptoms of infection, thus hindering the recognition of potential ineffectiveness of the antibiotic therapy. If infection does not improve or becomes worse during administration of an ophthalmic corticosteroid, the drug should be discontinued and other appropriate therapy initiated.

References

  1. "Product Information. FML Ophthalmic Suspension (fluoromethalone ophthalmic)." Allergan Inc, Irvine, CA.
  2. "Product Information. Decadron Ocumeter (dexamethasone ophthalmic)." Merck & Co, Inc, West Point, PA.
  3. "Product Information. Pred Forte (prednisolone ophthalmic)." Allergan Inc, Irvine, CA.
  4. "Product Information. HMS (medrysone ophthalmic)." Allergan Inc, Irvine, CA.
  5. "Product Information. Vexol (rimexolone ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.
  6. "Product Information. Lotemax (loteprednol ophthalmic)." Bausch and Lomb, Tampa, FL.
View all 6 references
Major

Ophthalmic corticosteroids (applies to Pred-Moxi-Nepaf) ocular toxicities

Major Potential Hazard, High plausibility. Applicable conditions: Cataracts, Glaucoma/Intraocular Hypertension

Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with ophthalmic corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure. If these agents are used for more than 10 days, the manufacturers recommend that intraocular pressure be routinely monitored, including in children. The equatorial and posterior subcapsular portions of the lens should be examined for changes.

References

  1. Foster CS, Alter G, Debarge LR, Raizman MB, Crabb JL, Santos CI, Feiler LS, Friedlaender MH "Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis." Am J Ophthalmol 122 (1996): 171-82
  2. "Product Information. Vexol (rimexolone ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.
  3. Francois J "Corticosteroid glaucoma." Ann Ophthalmol 9 (1977): 1075-80
  4. Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42
  5. "Product Information. Lotemax (loteprednol ophthalmic)." Bausch and Lomb, Tampa, FL.
  6. Butcher JM, Austin M, McGalliard J, Bourke RD "Bilateral cataracts and glaucoma induced by long term use of steroid eye drops." BMJ 309 (1994): 43
  7. "Product Information. Decadron Ocumeter (dexamethasone ophthalmic)." Merck & Co, Inc, West Point, PA.
  8. "Product Information. FML Ophthalmic Suspension (fluoromethalone ophthalmic)." Allergan Inc, Irvine, CA.
  9. Leibowitz HM, Bartlett JD, Rich R, Mcquirter H, Stewart R, Assil K "Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids." Arch Ophthalmol 114 (1996): 933-7
  10. "Product Information. Pred Forte (prednisolone ophthalmic)." Allergan Inc, Irvine, CA.
  11. Godel V, Regenbogen L, Stein R "On the mechanism of corticosteroid-induced ocular hypertension." Ann Ophthalmol 10 (1978): 191-6
  12. "Product Information. HMS (medrysone ophthalmic)." Allergan Inc, Irvine, CA.
  13. Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976): 492-5
View all 13 references

Pred-Moxi-Nepaf (moxifloxacin / nepafenac / prednisolone ophthalmic) drug interactions

There are 107 drug interactions with Pred-Moxi-Nepaf (moxifloxacin / nepafenac / prednisolone ophthalmic)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.